<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="468">
  <stage>Registered</stage>
  <submitdate>8/09/2005</submitdate>
  <approvaldate>14/09/2005</approvaldate>
  <actrnumber>ACTRN12605000408684</actrnumber>
  <trial_identification>
    <studytitle>Safety and pharmacokinetic study of ACV1, a potential neuropathic pain treatment.</studytitle>
    <scientifictitle>A Randomised, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Doses of ACV1 in Healthy Adult Male Subjects.</scientifictitle>
    <utrn />
    <trialacronym>N/A</trialacronym>
    <secondaryid>Metabolic Pharmaceuticals Ltd.: METACV101</secondaryid>
    <secondaryid>CM6605</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neuropathic pain</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Randomised, placebo-controlled, double-blind, single and mutliple (7 day) ascending dose, Phase 1 study of subcutaneous ACV1 in healthy adult male volunteers.</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety of both single and multiple subcutaneous doses of ACV1 when administered to healthy adult male volunteers.  The data available for review includes clinical lab tests, vital signs, ECGs and adverse events</outcome>
      <timepoint>Collected to a minimum of 24 hours post-dose for single dose groups and 7 days for multiple dose groups.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Tolerability of both single and multiple subcutaneous doses of ACV1 when administered to healthy adult male volunteers.  The data available for review includes clinical lab tests, vital signs, ECGs and adverse events</outcome>
      <timepoint>Collected to a minimum of 24 hours post-dose for single dose groups and 7 days for multiple dose groups.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the pharmacokinetics of both single and multiple doses of subcutaneous ACV1.</outcome>
      <timepoint>Up to 24 hours post-dose. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the pharmacodynamic effects of ACV1 when administered subcutaneously. </outcome>
      <timepoint>This will be assessed during the multiple-dose groups by evaluation of touch sensitivity using Von Frey filaments on Day 1 and Day 6 pre-dose, and up to 8 hours post-dose. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>An electrical stimulation test will be carried out during the multiple dosing.</outcome>
      <timepoint>Pre-dose on Day 1, and pre-dose and up to 8 hours post-dose on Days 2 and 7.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Weight &lt;= 100 kg, BMI 19 to 30, generally healthy, adequate venous access, fluent English, have given written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>49</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Hypersensitivity, medical conditions, organ dysfunction, drug or alcohol abuse, taking medication.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Vials containing the drug are numbered with a patient ID number to conceal treatment allocation.  Formulations are provided in ready-to-administer syringes so medical and nursing staff remind blind.</concealment>
    <sequence>Random allocation was carried out manually.  Treatment assignment ensures that within each dose group only one subject receives placebo and four subjects receive active treatment.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>23/06/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>5000</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Metabolic Pharmaceuticals Ltd.</primarysponsorname>
    <primarysponsoraddress>Level 3, 509 St Kilda Rd
Melbourne
VIC 3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Metabolic Pharmaceuticals Ltd</fundingname>
      <fundingaddress>Level 3, 509 St Kilda Rd
Melbourne 3000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Ausindustry</fundingname>
      <fundingaddress>9th Floor KPMG House
161 Collins St
Melbourne 3000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study is to assess the safety and tolerability of subcutaneous doses of ACV1 in healthy adult males.</summary>
    <trialwebsite>www.metabolic.com.au</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>CMAX - Clinical (a division of IDT Australia)</ethicname>
      <ethicaddress>Level 5 East Wing
Royal Adelaide Hospital
North Terrace
Adelaide 5000</ethicaddress>
      <ethicapprovaldate>18/08/2006</ethicapprovaldate>
      <hrec>CM6605</hrec>
      <ethicsubmitdate>17/07/2006</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Caroline Herd</name>
      <address>Metabolic Pharmaceuticals Ltd
Level 3
509 St Kilda Rd
Melbourne VIC 3004</address>
      <phone>+61 3 98605700</phone>
      <fax>+61 3 98605777</fax>
      <email>Clinicaltrials@metabolic.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Caroline Herd</name>
      <address>Metabolic Pharmaceuticals Ltd
Level 3
509 St Kilda Rd
Melbourne VIC 3004</address>
      <phone>+61 3 98605700</phone>
      <fax>+61 3 98605777</fax>
      <email>Clinicaltrials@metabolic.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lyndal Borrell</name>
      <address>Metabolic Pharmaceuticals Ltd
Level 3, 509 St Kilda Rd
Melbourne
VIC 3004</address>
      <phone>+ 61 3 98605700</phone>
      <fax>+61 3 98605777</fax>
      <email>lyndal.borrell@metabolic.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>